Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from HUTCHMED (China) ( (HK:0013) ) is now available.
HUTCHMED (China) Limited announced that as of June 30, 2025, its issued share capital consisted of 872,111,470 ordinary shares, each carrying one voting right. This figure is significant for shareholders to determine their interest in HUTCHMED shares under the Financial Conduct Authority’s rules. The announcement highlights the company’s transparent approach to shareholder engagement and may impact how stakeholders perceive their investments in the company.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company aims to bring drug candidates from in-house discovery to patients globally, with its first three medicines marketed in China and one approved worldwide, including in the US, Europe, and Japan.
See more data about 0013 stock on TipRanks’ Stock Analysis page.